daridorexant Quviviq
Selected indexed studies
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (Transl Psychiatry, 2025) [PMID:40555730]
- Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. (Lancet Neurol, 2022) [PMID:35065036]
- Daridorexant (Quviviq) for insomnia. (Med Lett Drugs Ther, 2022) [PMID:35802843]
_Worker-drafted node — pending editorial review._
Connections
daridorexant Quviviq is a side effect of
Sources
- Insomnia Management: A Review and Update. (2023) pubmed
- Daridorexant for the Treatment of Insomnia. (2022) pubmed
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. (2025) pubmed
- Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. (2022) pubmed
- Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study. (2024) pubmed
- Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. (2023) pubmed
- Daridorexant: First Approval. (2022) pubmed
- Daridorexant (Quviviq) for insomnia. (2022) pubmed
- The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. (2023) pubmed
- Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. (2024) pubmed